Outset Medical (NASDAQ:OM) is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios. The system’s intuitive touchscreen interface and automated processes enable clinicians and nursing staff to focus more on patient care and less on equipment management. Remote connectivity features facilitate data sharing, allowing care teams to monitor treatment parameters, troubleshoot issues and optimize protocols in real time.
Founded in 2010 and headquartered in San Jose, California, Outset Medical secured FDA clearance for the Tablo system in 2017 and received CE mark approval for distribution in Europe shortly thereafter. Since its initial public offering in 2019, the company has expanded its geographic footprint to include markets across North America, Western Europe and the Asia-Pacific region. Strategic partnerships and distribution agreements have further enabled the rollout of Tablo in a variety of clinical environments, from large hospital networks to smaller dialysis centers.
Under the leadership of CEO Leslie Trigg, Outset Medical continues to invest in research and development aimed at enhancing treatment efficiency, patient safety and overall care quality. The company’s mission centers on transforming the delivery of dialysis by making therapy more accessible, adaptable and patient-centric, while driving down the total cost of care through innovative technology solutions.
